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BRIEF DEFINITIVE REPORT
        12(S)-hydroxyheptadeca-5Z, 8E, 10E  –  trienoic 
acid (12-HHT) was fi  rst identifi  ed as an enzy-
matic product of arachidonic acid metabolism 
by cyclooxygenase (Cox) derived from the ve-
sicular gland of sheep and human platelets (  1  ). 
Thromboxane A  2   (TXA  2  ) synthase catalyzes 
the conversion of prostaglandin H  2   (PGH  2  ) to 
TXA  2  , 12-HHT, and malondialdehyde (MDA) 
in an equimolar ratio. TXA  2   is a potent stimu-
lator of platelet aggregation and vascular con-
striction through activating the TX receptor, a 
member of the family of G protein  –  coupled 
receptors. TXA  2   has also been shown to play a 
major role in thrombosis, vasoconstriction, the 
proliferation of vascular smooth muscle cells, and 
immune regulation (  2  ). However, the functional 
role of 12-HHT remains elusive. 
  Arachidonic acid is also converted by 5-li-
poxygenase (5-LO) to yield another class of 
metabolites termed leukotrienes and lipoxins 
(  3, 4 ). 5(S), 12(R)-dihydroxy-6, 14-cis-8, 10-trans-
eicosatetraenoic acid (leukotriene B  4   [LTB  4  ]) is 
an extremely potent lipid infl  ammatory mediator. 
Biosynthesis of LTB  4   from membrane phospho-
lipids occurs via the coordinated and sequential 
actions of cytosolic phospholipase A  2      , 5-LO, 
and LTA  4   hydrolase (  5  –  8  ). Previously, we identi-
fi  ed two distinct G protein  –  coupled receptors 
that bind to LTB  4  , LTB  4   receptor-1 (BLT1), 
and BLT2 (  9, 10  ). BLT1 is a high-affi   nity LTB  4   
receptor expressed in myeloid and lymphoid 
cells (  11  ), whereas BLT2 is a low-affi   nity LTB  4   
receptor that is expressed rather ubiquitously (  12  ). 
A recent study has shown that an LTB  4    –  BLT1 
signaling cascade regulates early phase immuno-
logical reactions by recruiting T lymphocytes 
(  13  ). The LTB  4    –  BLT1 axis is also important in 
atherogenesis (  14  ), infl  ammatory bowel disease, 
and rheumatoid arthritis. In contrast, the bio-
logical role of BLT2 has not been clearly defi  ned. 
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  Activated blood platelets and macrophages metabolize prostaglandin H  2   into thromboxane 
A  2   and 12(S)-hydroxyheptadeca-5Z, 8E, 10E  –  trienoic acid (12-HHT) in an equimolar ratio 
through the action of thromboxane synthase. Although it has been shown that 12-HHT is 
abundant in tissues and bodily fl  uids, this compound has long been viewed as a by-product 
lacking any specifi  c function. We show that 12-HHT is a natural ligand for leukotriene B  4   
(LTB  4  ) receptor-2 (BLT2), a G protein  –  coupled receptor that was originally identifi  ed as a 
low-affi  nity receptor for LTB  4  . BLT2 agonistic activity in lipid fractions from rat small 
intestine was identifi  ed as 12-HHT using high-performance liquid chromatography and 
mass spectrometry. Exogenously expressed BLT2 in mammalian cells was activated by 
synthetic 12-HHT, as assessed by guanosine 5    -  O  -(3-thio) triphosphate binding, the activa-
tion of intracellular signaling pathways, and chemotaxis assay. Displacement analysis using 
[  3  H]LTB  4   showed that 12-HHT binds to BLT2 with a higher affi  nity than LTB  4  . Lipid extracts 
from cyclooxygenase 1  –  defi  cient mice failed to activate BLT2. Bone marrow  –  derived mast 
cells (BMMCs) isolated from wild-type mice migrated toward a low concentration of 
12-HHT, whereas BMMCs from BLT2-defi  cient mice did not. We conclude that 12-HHT is a 
natural lipid agonist of BLT2 in vivo and induces chemotaxis of mast cells. 760 12-HHT IS A NATURAL LIGAND FOR BLT2 | Okuno et al.
as a natural endogenous ligand for BLT2. This result was 
somewhat surprising, as 12-HHT has long been considered 
merely a by-product of the thromboxane synthase reaction. 
Synthetic 12-HHT activated human and mouse BLT2, based 
on intracellular signalings and binding assays. In addition, 
12-HHT induced chemotaxis in bone marrow  –  derived mast 
cells (BMMCs) derived from WT mice but not from BLT2-
defi  cient mice. 
    RESULTS AND DISCUSSION   
  Acetone-soluble lipids from rat small intestine activate BLT2 
  We extracted lipids from several rat organs and analyzed their 
ability to activate BLT2 that was heterologously expressed 
Recently, we showed that when BLT2 is over  expressed 
in cells, it can be activated by 1  –  10-  μ  M concentrations of 
hydroxyeicosatetraenoic acids (HETEs) (  15  ). We have also 
identified a synthetic BLT2-specific agonist that activates 
human and mouse BLT2 at a lower concentration than 
LTB  4   (  16  ). These results suggest that there are other, as yet 
unidentifi  ed intrinsic BLT2 agonists. To identify intrinsic ag-
onists of BLT2, we examined the activation of BLT2 by lipid 
extracts from various rat tissues. Lipid fractions from the 
rat small intestine contained BLT2 agonistic activity, which 
was distinct from LTB  4  , as assessed by HPLC. We determined 
the structure of the bioactive lipid using reverse-phase HPLC 
(RP-HPLC) and mass spectrometry, and identifi  ed 12-HHT 
    Figure 1.         Structural determination of a BLT2 agonist isolated from the rat intestine.   Total lipid was extracted from the rat small intestine by the 
Bligh and Dyer method and separated into acetone-soluble and insoluble fractions. (A) CHO cells stably expressing BLT1 or BLT2 were stimulated with lipid 
fractions, and activity was monitored by cytosensor assay. (B) Acetone-soluble lipids from the rat small intestine were analyzed by RP-HPLC (MeOH/H  2 O/
AcOH = 70:30:0.01), and fractions were collected every 1 min. The agonistic activity was examined by cytosensor assay. (C) Tandem mass spectra of 
12-HHT (synthetic) and the m/z 279.2 peak of fraction 13. The proposed fragmentation is indicated.     JEM VOL. 205, April 14, 2008  761
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and solubility of the molecule, we speculated that the target 
agonist molecule was C17H27O3 (m/z 279.196), with one 
hydroxyl group and one carboxyl group. These results strongly 
implicated 12-HHT as the lipid agonist because the formula 
of 12-HHT is C17H27O3, and 12-HHT is a C-17 unsatu-
rated fatty acid with one hydroxyl group and one carboxyl 
group. Furthermore, in the enhanced product scan mode, 
the fragmentation patterns of chemically synthesized 12-HHT 
and the target agonist molecule in fraction 13 were similar 
(  Fig. 1 C  ). Collectively, these results indicated that the BLT2-
active lipid in fraction 13 was 12-HHT. To examine the 
retention times of 12-HHT and the bioactive lipid, we ana-
lyzed a mixture of LTB  4  , 12-HHT, and 12- and 15-HETE 
by RP-HPLC. 12-HHT (Fig. S1 A) and the bioactive 
lipid (Fig. S1 B) eluted in the same fraction, between LTB  4   
and HETEs, and both were able to activate BLT2 in the cyto-
sensor assay. 
in Chinese hamster ovary (CHO) cells using a cytosensor 
microphysiometor assay. Cytosensor measures proton fl  ux 
that is not dependent on or biased by intracellular signals 
(  17  ). CHO cells that stably expressed human BLT2 (CHO-
BLT2) were activated by total lipid and acetone-soluble lipid 
fractions from the rat small intestine, whereas cells that ex-
pressed human BLT1 (CHO-BLT1) and mock transform-
ants were not (  Fig. 1 A  ).   These results were consistent with 
the high expression of mouse BLT2 in the small intestine 
(  16  ). The acetone-soluble lipid fraction from the rat small 
intestine was fractionated by RP-HPLC, and the activities 
of the collected fractions were analyzed using a cytosensor. 
We also analyzed authentic LTB  4  , 12-HETE, and 15-HETE 
(12- and 15-HETE are weak agonists for BLT2) by RP-
HPLC using the same conditions. LTB  4   eluted in fraction 
6, 15-HETE eluted in fraction 13, and 12-HETE eluted 
in fractions 14 and 15 (Fig. S1 A, available at http://www.jem
.org/cgi/content/full/jem.20072329/DC1), and both CHO-
BLT1 and CHO-BLT2 cells were activated after exposure 
to fraction 6 (Fig. S1 A). When we examined the activity of 
the fractionated acetone-soluble lipid from rat intestine, we 
found that fractions 7 and 8 activated CHO-BLT2 cells but 
not CHO-BLT1 cells (Fig. S1 B). These results indicated 
that there is a BLT2-specifi  c agonist in the lipid fraction of 
the rat intestine, and that this activity is distinct from LTB  4   
or HETEs. Previously, we reported that several HETEs also 
weakly activate BLT2 (  15  ). However, in the current analy-
sis, it appeared that the concentration of HETEs in fractions 
13, 14, and 15 was too low to activate BLT2 (Fig. S1 A). 
Therefore, we focused on identifying the BLT2 agonist in 
fractions 7 and 8. 
  Determination of lipid structure by HPLC 
and mass spectrometry 
  To determine the structure of the BLT2-active lipid from 
the rat small intestine, we analyzed the acetone-soluble lipid 
fraction by RP-HPLC and mass spectrometry. To improve 
the separation on RP-HPLC, we used a solvent of metha-
nol/H  2  O/AcOH at a ratio of 70:30:0.01 (vol/vol/vol), 
rather than 75:25:0.01, to extend the retention time. Under 
these conditions, fraction 13 showed the highest BLT2 ago-
nist activity, and mock transformants or CHO-BLT1 cells 
were not activated by this fraction (  Fig. 1 B  ). Fractions 11  –  15 
were then subjected to electrospray ionization  –  mass spec-
trometry by fl  ow injection. The main peak in fraction 13 was 
located at m/z 279.2 and represented the likely candidate for 
the BLT2-active molecule. This peak was low in fractions 12 
and 14 (Fig. S1 C). Using the enhanced resolution mode, we 
determined that the detailed numerical value of the active 
molecule was 279.18 (Fig. S1 D). LTB  4   is a C-20 unsaturated 
fatty acid with two hydroxyl groups and one carboxyl group, 
and 12- and 15-HETE are C-20 unsaturated fatty acids with 
one hydroxyl group and one carboxyl group (Fig. S1 E). In 
our analysis, the BLT2-active molecule eluted between the 
fractions that contained LTB  4   and HETEs. Based on calcu-
lated formulas and retention time, which refl  ects the polarity 
    Figure 2.         12    -HHT binds BLT and activates G proteins.  
(A and B) The dose  –  response curves of the [  35 S]GTP   S binding assay using 
membrane preparations of CHO cells stably expressing BLT1 or BLT2. 
Data represent the mean   ±   SEM (  n   = 3). (C) Membrane prepara-
tions of CHO-BLT2 cells were incubated with 5 nM [  3 H]LTB 4 ,  and 
specific binding was measured in the presence of the indicated con-
centrations of LTB  4   or 12-HHT, as depicted. Data represent the 
mean   ±   SEM  ( n   = 3).     762 12-HHT IS A NATURAL LIGAND FOR BLT2 | Okuno et al.
preparations from CHO-BLT2 cells as compared with CHO-
BLT1 cells (  Fig. 2 B  ). Although ligand-binding experiments 
are the most defi  nitive method for demonstrating ligand  – 
receptor interactions, radiolabeled [  3  H]12-HHT is not readily 
available. Therefore, we performed a displacement assay using 
[  3  H]LTB  4   and either 12-HHT or LTB  4  . In membrane prepa-
rations of CHO-BLT2 cells, the IC  50   values of 12-HHT and 
LTB  4   in the presence of 5 nM [  3  H]LTB  4   were 2.8 and 25 nM, 
respectively (  Fig. 2 C  ). These results suggested that BLT2 is a 
high-affi   nity receptor for 12-HHT, and that 12-HHT and 
LTB  4   occupy the same binding site on BLT2. 
  Previously, we showed that the activation of BLT1 and 
BLT2 is coupled to the Gi and Gq families of G proteins (  12, 
18  ). To determine whether 12-HHT could induce the acti-
vation of Gq, we examined 12-HHT  –  dependent calcium 
  12-HHT activates BLT2 that is heterologously expressed 
in mammalian cells 
  Although cytosensor analysis is a useful screening tool for the 
identifi  cation of compounds based on their ability to activate 
cell metabolism, it does not identify specifi  c intracellular sig-
naling pathways that are activated after receptor engagement. 
To determine whether 12-HHT  –  mediated activation of 
BLT2 induced the GDP-GTP exchange activity of G pro-
teins, we performed a guanosine 5    -  O  -(3-thio) triphosphate 
(GTP    S) binding assay using membrane preparations from 
CHO-BLT1 and CHO-BLT2 cells. 12-HHT increased 
GTP    S binding in membrane preparations from CHO-BLT2 
cells in a dose-dependent manner, but not in membranes from 
CHO-BLT1 cells or mock transformants (  Fig. 2 A  ).   LTB  4   
induced a much lower level of GTP    S binding in membrane 
    Figure 3.         12-HHT  –  induced intracellular signaling is mediated by BLT2.   (A and B) Intracellular calcium mobilization in (A) CHO-BLT2 and (B) CHO-
BLT1 cells after exposure to 12-HHT or LTB  4   was analyzed by FlexStation (MDS Analytical Technologies). Data represent the mean   ±   SEM (  n   = 3). (C) The 
dose  –  response curves of the IP accumulation assay in coexpressing COS-7 cells transfected with BLT2 and G14. Data represent the mean   ±   SEM (  n   =  3). 
(D) CHO cells stably expressing BLT1 or BLT2 were stimulated with 50   μ  M of forskolin and the indicated concentrations of LTB  4   and 12-HHT, and the levels 
of cAMP in the cells were determined. Data represent the mean   ±   SEM (  n   = 4). (E and F) Chemotaxis assay of CHO-BLT1 and CHO-BLT2 cells was examined 
using a Boyden chamber assay. Data represent the mean   ±   SEM (  n   =  3).   JEM VOL. 205, April 14, 2008  763
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tussis toxin completely abolished 12-HHT  –  induced chemo-
taxis (Fig. S2 D). These results suggested that 12-HHT is a 
high-affi   nity ligand for human and mouse BLT2 and activates 
Gq and Gi family G proteins. 
  Platelet-derived 12-HHT activates BLT2 
  Activated platelets produce TXA  2  , 12-HHT, and MDA 
from PGH  2  . We stimulated human platelets with arachi-
donic acid and extracted the lipid fraction from these cells. 
The extracted lipids were fractionated by RP-HPLC, and 
the fractions were analyzed by cytosensor assay.   Fig. 4, A and B   
mobilization in CHO-BLT1 and CHO-BLT2 cells. The 
EC  50   values of 12-HHT and LTB  4   in CHO-BLT2 cells were 
19 and 142 nM, respectively (  Fig. 3 A  ).   The EC  50   value of 
LTB  4   in CHO-BLT1 cells was 6.6 nM, whereas 12-HHT 
failed to induce calcium mobilization in CHO-BLT1 cells, 
even at concentrations as high as 3.3   μ  M (  Fig. 3 B  ). The acti-
vation of receptors that are coupled to Gq family proteins in-
duces phospholipase C activation, followed by the production 
of inositol triphosphate (IP  3  ). To identify the Gq family 
members that are involved 12-HHT  –  mediated activation of 
BLT2, we performed an IP accumulation assay using COS-7 
cells that were transiently cotransfected with expression vec-
tors for BLT2 and various Gq family proteins. There was a 
signifi  cantly higher level of IP accumulation in cells that co-
expressed BLT2 and G14 (Fig. S2 A, available at http://
www.jem.org/cgi/content/full/jem.20072329/DC1), whereas 
coexpression of Gq and G11 with BLT2 resulted in a rela-
tively weak increase and no eff  ect of G16 in IP accumulation. 
These fi  ndings are in contrast to previous data in BLT1-
mediated signaling (  18  ). In cells that coexpressed BLT2 and G14, 
the EC  50   of 12-HHT and LTB  4   for the accumulation of IP 
was 5.4 and 43 nM, respectively (  Fig. 3 C  ). 12-HHT also 
activated mouse BLT2, as shown by IP accumulation assay 
using cells that were cotransfected with expression vectors for 
mouse BLT2 and G14 (Fig. S2 B). 
  The activity that resulted from the combined expression of 
specifi  c receptors and G proteins may refl  ect the expression 
pattern or function of these proteins in vivo. Although all Gq 
proteins share a capacity to activate phospholipase C    , they 
diff  er markedly in their biochemical properties and tissue distri-
bution. Gq and G11 are the most similar among this class of G 
proteins and are fairly widely expressed. G14 exhibits a more 
diverse expression pattern (kidney, liver, lung, and testis), 
whereas G16 expression appears to be limited to hematopoietic 
cells. Human and mouse BLT1 are expressed exclusively in 
leukocytes, which also express G16. Human BLT2 expression 
correlates with the distribution of Gq, G11, and G14, which 
suggests that BLT2 is coupled to these G proteins in vivo  .   
  To determine whether 12-HHT could induce the activa-
tion of Gi proteins, we performed a series of cAMP and che-
motaxis assays in CHO-BLT1 and CHO-BLT2 cells. The 
IC  50   of 12-HHT and LTB  4   for adenylyl cyclase inhibition in 
CHO-BLT2 cells was 1 and 14 nM, respectively (  Fig. 3 D  ). 
12-HHT  –  dependent adenylyl cyclase inhibition in CHO-
BLT2 cells was completely blocked by pretreatment with 
pertussis toxin (Fig. S2 C). The IC  50   of LTB  4   in CHO-BLT1 
cells was 0.3 nM, whereas 12-HHT had no eff  ect (  Fig. 3 D  ). 
Previously, we showed that LTB  4   induces chemotaxis through 
the activation of BLT2 (  12, 15, 16  ). To determine whether 
12-HHT also stimulated chemotaxis through BLT2, we per-
formed a Boyden chamber chemotaxis assay of CHO-BLT2 
cells exposed to 12-HHT or LTB  4  . The concentration of 12-
HHT required for maximal chemotaxis was 30 nM, whereas 
that of LTB  4   was   >  1,000 nM (  Fig. 3, E and F  ). 12-HHT 
failed to induce chemotaxis in CHO-BLT1 cells and mock 
cells (  Fig. 3 F  ). Pretreatment of CHO-BLT2 cells with per-
    Figure 4.         Activation of BLT2 by platelet-derived 12-HHT requires 
Cox-1.   (A and B) Human platelets were pretreated with vehicle (A) or 
10   μ  M aspirin (B) and then incubated with 10   μ  M of arachidonic acid. Lipids 
were extracted and analyzed by RP-HPLC. Fractions were collected every 
1 min, and agonistic activity toward CHO-BLT1 and CHO-BLT2 cells was 
analyzed by cytosensor assay. The continuous and dashed lines show 
absorbance at 235 and 270 nm, respectively. (C) Lipids were extracted 
from the small intestines of Cox-1  –  defi  cient and WT mice, and agonistic 
activity toward CHO-mock, CHO-BLT1, and CHO-BLT2 cells was examined 
by cytosensor assay. ATP was used as a control for the activation of 
endogenous purinergic receptors in CHO cells.     764 12-HHT IS A NATURAL LIGAND FOR BLT2 | Okuno et al.
ported that BLT2 was expressed in mouse platelets (  19  ). 12-
HHT did not display agonistic activity in platelet aggregation 
(unpublished data); thus, the role of 12-HHT and 12-HETE 
in platelet function remains to be determined. 
  Lipids extracted from Cox-1  –  defi  cient mice fail 
to activate BLT2 
  It has been shown that Cox activity is important for 12-HHT 
production. To determine the eff  ect of Cox-1 defi  ciency on 
the production of 12-HHT, we extracted lipids from the 
small intestines of Cox-1  –  defi  cient mice. As seen in   Fig. 4 C  , 
lipids from Cox-1  –  defi  cient mice contained much lower 
BLT2 agonistic activity than those from WT mice. These re-
sults indicated that Cox-1 is required for the biosynthesis of 
12-HHT in vivo, and that 12-HHT is the major ligand of 
BLT2 in the intestine. 
  12-HHT induces the migration of BMMCs through BLT2 
  Lundeen et al. (  20  ) previously reported that mouse BMMCs 
(mBMMCs) express BLT2 and migrate in response to LTB  4   
show the HPLC chromatograph and the results of the cyto-
sensor assays for each fraction.   The BLT2-active fractions 
from human platelets were fractions 7 and 8 (  Fig. 4 A  ). Pre-
treatment of platelets with 10   μ  M aspirin completely abol-
ished BLT2 agonistic activity, and there was a concomitant 
loss of UV absorbance at 235 nm in fractions 7 and 8 (  Fig. 4 B  ). 
Aspirin treatment resulted in the appearance of weak BLT2 
agonistic activity in fractions 14 and 15, and a high level 
of absorbance at 235 nm in these fractions. Based on the UV 
spectrum and the HPLC profi  le, we speculate that this weak 
agonistic activity is 12-HETE (Fig. S1 A). None of the 
fractions exhibited UV absorbance at 270 nm or BLT1-
specifi  c activity, which suggested that platelets do not pro-
duce detectable amounts of LTB  4  . These results indicated 
that human platelets produce 12-HHT, a natural agonist of 
BLT2, and that Cox activity is required for the biosynthesis 
of 12-HHT. It is likely that the inhibition of the Cox path-
way in platelets by pretreatment with aspirin increased the 
production of 12-HETE (  Fig. 4 B  ) by shunting arachidonic 
acid from the Cox to the 12-LO pathway (  1  ). Shao et al. re-
    Figure 5.         12-HHT  –  induced mBMMC chemotaxis is mediated by BLT2.   Chemotaxis of WT BMMCs in response to (A) LTB  4  , (B) 12-HHT, and (C) 25 ng/ml 
SCF. Chemotaxis of BLT1-KO BMMCs in response to (D) LTB  4  , (E) 12-HHT, and (F) 25 ng/ml SCF. Chemotaxis of BLT2-KO BMMCs in response to (G) LTB  4 , 
(H) 12-HHT, and (I) 25 ng/ml SCF. Data represent the mean   ±   SEM (  n   = 3). (J) Schematic representation of the production and action of 12-HHT.     JEM VOL. 205, April 14, 2008  765
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intercellular messenger between platelets, macrophages, and 
mast cells in vivo. 
  MATERIALS AND METHODS 
  Materials.     LTB  4  , 12-HHT, and 12- and 15-HETE were purchased from 
Cayman Chemical. cDNAs encoding the various G proteins were obtained 
from Guthrie cDNA Resource Center. pcDNA3-HA-BLT1 and BLT2 
were previously described (  12, 16, 27  ). 
  Cell culture, transfection, and cell sorting.     All cells were established 
and maintained as previously described (  18  ). 
  Extraction of lipid fractions, RP-HPLC, and mass spectrometry 
analysis.     Rats were purchased from Japan Clea, and Cox-1  –  defi  cient mice 
were purchased from Taconic. All animal experiments were conducted in 
accordance with the Guidelines of Animal Research at the University of 
Tokyo and Kyushu University and were approved by the Animal Ethics 
Committees of both universities. Small intestines of adult female Wistar rats 
or mice were homogenized in chloroform/methanol (1:2; C/M), and lipids 
were extracted by the Bligh and Dyer method. To separate acetone-soluble 
and insoluble fractions, dried lipids were reconstituted with acetone and 
incubated for 1 h at 4  °  C. After centrifugation at 1,000   g   for 5 min, the pellet 
was washed twice with ice-cold acetone. Acetone-soluble fractions were 
combined, dried, and dissolved in C/M. The HPLC column (4.6   ×   150 
mm; COSMOSIL 5C18-AR; Nacalaitesque) was equipped with a diode 
array detector (System Gold module 168; Beckman Coulter) and eluted with 
MeOH/H  2  O/AcOH at a fl  ow rate of 1 ml/min. Absorbance was moni-
tored at 235 and 270 nm. Mass spectrometry analyses were performed using 
a 4000 Q-TRAP system (Applied Biosystems). Spectra were recorded in 
negative ion mode, the composition of the mobile phase was acetonitrile/
methanol/water 6:7:2 (plus 0.1% ammonium formate), and the fl  ow rate 
was 4   μ  l/min      1  . 
  Binding and signaling assays.     Cytosensor, calcium mobilization (  27  ), 
cAMP, IP accumulation, GTP    S, LTB  4   binding, and chemotaxis assays (  18  ) 
were performed as described previously. 
  Preparation of human platelets and arachidonic acid stimulation.   
  50 ml of human blood were collected from healthy volunteers under written 
informed consent, added to 1 ml of 0.25 M EDTA, and subjected to cen-
trifugation at 1,400   g   for 3 min to obtain platelet-rich plasma. The super-
natants were centrifuged twice at 100   g   for 25 min to remove leukocytes, 
and then the supernatant was centrifuged at 1,000   g   for 17 min. The resulting 
pellets were resuspended in 2 ml of wash buff  er (0.113 M NaCl, 4.3 mM 
K  2  HPO  4  , 4.3 mM K  2  HPO  4  , 4.3 mM NaHPO  4  , and 5.5 mM sucrose [pH 
6.5]), washed twice, and resuspended in 4 ml of resuspension buff  er (0.14 M 
NaCl, 5.5 mM glucose, and 15 mM Tris-HCl [pH 7.5]). 3   ×   10  8   platelets 
were incubated with or without 1 mM aspirin at 37  °  C for 5 min and stimu-
lated with 50   μ  M of arachidonic acid at 37  °  C for 15 min. The lipid fraction 
was recovered using C/M. 
  Chemotaxis of BMMCs.     Mice that were defi  cient in BLT1 (  21  ) and 
BLT2 (unpublished data) were backcrossed to BALB/c mice for 10 genera-
tions. BMMCs were cultured in RPMI 1640 medium supplemented with 
10% fetal calf serum, 0.1 mM of nonessential amino acids, and 50% WEHI-3 
cell-conditioned medium (WEHI-3 cells were provided by M. Murakami, 
Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). The BMMC 
migration assay was performed as previously described (  20  ). 
  Online supplemental material.     Fig. S1 shows the behavior on HPLC 
and the structural determination of BLT2 ligand from rat intestine. Fig. 
S2 shows 12-HHT  –  induced intracellular signaling through BLT2. Fig. S3 
shows the expression of c-  kit   and Fc    RI on mBMMCs used in this ex-
periment. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20072329/DC1. 
and 12-HETE. We performed a similar migration assay using 
mBMMCs derived from WT, BLT1-KO (  21  ), and BLT2-
KO (unpublished data) mice. The maturation of mast cells was 
confi  rmed by fl  ow cytometry (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20072329/DC1). BMMCs 
from WT and BLT2-KO mice migrated in response to LTB  4  , 
whereas cells from BLT1-KO mice did not (  Fig. 5, A, D, and G  ).   
WT and BLT1-KO cells migrated in response to 12-HHT, 
whereas BLT2-KO cells did not (  Fig. 5, B, E, and H  ). As a 
positive control, we observed that stem cell factor (SCF) in-
duced robust chemotaxis through the c-  kit   receptor in WT, 
BLT1-KO, and BLT2-KO BMMCs to a similar extent (  Fig. 5, 
C, F, and I  ). LTB  4   and 12-HHT induced weaker chemotaxis 
in mBMMCs than SCF, as reported previously (  20  ), and we 
speculate that this is caused by the lower expression of BLT1 and 
BLT2 in these cells. These results indicate that functional BLT2 
is expressed in BMMCs and mediates 12-HHT  –  dependent 
cell migration. 
  Putative biological roles of the 12-HHT  –  BLT2 signaling axis 
  Although the biological role of the BLT1  –  LTB  4   signaling 
axis has been investigated in detail, the physiological and 
pathological roles of BLT2 remain largely unknown. Our 
fi  ndings demonstrate that platelets produce 12-HHT in a Cox-
dependent manner, and that 12-HHT functions as a BLT2 
ligand. We also demonstrated that 12-HHT induces chemo-
taxis in mast cells through the activation of endogenous BLT2. 
In addition to their role in the allergic response, mast cells 
are multipotent eff  ector cells in the formation of athero-
thrombosis (  22  ). Atherogenic plaques consist of mast cells, 
macrophages, and platelets, all of which produce TXA  2   and 
12-HHT (  23, 24  ). We previously reported that mouse BLT2 
is expressed in mouse keratinocytes, and that LTB  4   and BLT2-
specifi  c agonists induced extracellular signal-regulated kinase 
activation and cell migration (  16  ). Thus, 12-HHT also may 
activate keratinocytes in vivo  .   
  MDA is produced along with 12-HHT from PGH  2  , and 
forms adducts with the proteins or phospholipids. Such ad-
ducts have been detected in atherosclerotic lesions of the 
human aorta, suggesting that they may play a role in athero-
genesis (  25  ). MDA has also been shown to form endogenous 
DNA adducts that may contribute to human genetic diseases 
and cancer (  26  ). Thus, the synergistic activity of 12-HHT 
and MDA in certain pathological conditions remains an in-
triguing possibility. 
  In summary, we have partially purifi  ed a natural ligand 
for BLT2 from the rat small intestine and identifi  ed the 
ligand as 12-HHT by liquid chromatography  –  mass spec-
trometry. 12-HHT is a very abundant metabolite of the ara-
chidonic acid cascade and has been considered to be merely a 
by-product, without any biological activity, for almost 30 yr. 
Our present fi  ndings provide evidence for a novel functional 
role of 12-HHT as a BLT2-ligand and represent a critical 
milestone in the understanding of the function of 12-HHT. 
Intrinsically expressed BLT2 in mast cells responds to 12-HHT 
(  Fig. 5  ), suggesting a novel important role of 12-HHT as an 766 12-HHT IS A NATURAL LIGAND FOR BLT2 | Okuno et al.
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